Compare BDN & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDN | DNA |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | N/A | 485 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.0M | 599.0M |
| IPO Year | 1995 | N/A |
| Metric | BDN | DNA |
|---|---|---|
| Price | $3.26 | $10.11 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 2 |
| Target Price | $3.50 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 1.7M | 1.3M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.67% | N/A |
| EPS Growth | ★ 9.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $484,454,000.00 | N/A |
| Revenue This Year | $12.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.47 | $5.37 |
| 52 Week High | $4.63 | $17.58 |
| Indicator | BDN | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 60.99 | 65.22 |
| Support Level | $2.91 | $7.59 |
| Resistance Level | $3.31 | $10.27 |
| Average True Range (ATR) | 0.09 | 0.68 |
| MACD | -0.00 | 0.17 |
| Stochastic Oscillator | 78.85 | 87.59 |
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.